Summary
Amarantus BioScience Holdings, Inc. (Amarantus) is a biotechnology company that discovers and develops treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. The company offers diagnostics and therapeutics pipeline products. Its diagnostics include lymphocyte proliferation test, nuropro blood test and DNA sequencing (NGS) assay. Amarantus provides DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. The company’s therapeutics pipeline products include eltoprazine and mesencephalic-astrocyte-derived neurotrophic factor (MANF). It also offers phenoguard protein discovery engine platform. The company provides products for cell cycle dysfunction, endoplasmic reticulum stress, astrocyte-neuron biology, neurodegeneration and apoptosis. Amarantus is headquartered in San Francisco, California, the US.
Amarantus Bioscience Holdings, Inc. (AMBS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Amarantus Bioscience Holdings, Inc., Medical Devices Deals, 2010 to YTD 2016 10
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Amarantus Therapeutics Raises US$1.3 Million In Venture Financing 13
Partnerships 14
Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 14
Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 15
Rainbow Biosciences Terminates Joint Venture With Amarantus BioSciences 16
Amarantus Enters Into Collaboration Agreement With Pioneer Valley Life Sciences 17
Licensing Agreements 19
Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 19
Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 20
Amarantus Bioscience to Enter into Licensing Agreement with University of Leipzig 22
Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 23
Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 24
Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 26
Equity Offering 27
Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 27
Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 29
Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 30
Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 32
Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 33
Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 34
Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 36
Amarantus BioSciences Enters Into Equity Funding Facility With Centurion Private Equity For US$10 Million 38
Debt Offering 39
Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 39
Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For US$1.6 Million 40
Acquisition 42
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 42
Jumpkicks Acquires Amarantus Therapeutics 44
Amarantus Bioscience Holdings, Inc. - Key Competitors 45
Key Employees 46
Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Tables
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Amarantus Bioscience Holdings, Inc., Deals By Therapy Area, 2010 to YTD 2016 9
Amarantus Bioscience Holdings, Inc., Medical Devices Deals, 2010 to YTD 2016 10
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Amarantus Therapeutics Raises US$1.3 Million In Venture Financing 13
Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 14
Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 15
Rainbow Biosciences Terminates Joint Venture With Amarantus BioSciences 16
Amarantus Enters Into Collaboration Agreement With Pioneer Valley Life Sciences 17
Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 19
Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 20
Amarantus Bioscience to Enter into Licensing Agreement with University of Leipzig 22
Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 23
Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 24
Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 26
Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 27
Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 29
Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 30
Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 32
Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 33
Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 34
Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 36
Amarantus BioSciences Enters Into Equity Funding Facility With Centurion Private Equity For US$10 Million 38
Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 39
Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For US$1.6 Million 40
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 42
Jumpkicks Acquires Amarantus Therapeutics 44
Amarantus Bioscience Holdings, Inc., Key Competitors 45
Amarantus Bioscience Holdings, Inc., Key Employees 46
Amarantus Bioscience Holdings, Inc., Subsidiaries 47
List of Figures
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Amarantus Bioscience Holdings, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Amarantus Bioscience Holdings, Inc., Medical Devices Deals, 2010 to YTD 2016 10
